The Food and Drug Administration will hold a meeting this summer to consider easing restrictions on more than a half dozen peptide injections, a group of unapproved therapies that have become popular BPC 157: Experimental Peptide Creates Risk for Athletes Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law When will the FDA reclassify BPC 157 to Category 1 Octagon AI The Peptide Craze Part 2: BPC 157, NAD and the Truth Behind the Longevity Molecule Hype